David Granlund

Research
My research interests are in industrial, health and public economics. Most of the research I have performed in the first two fields concerns the pharmaceutical market.

Current research projects:
Price effects of competition from parallel imports and therapeutic alternatives for patent protected pharmaceuticals [Priseffekter av konkurrens från parallellimport och terapeutiska alternativ för patentskyddade läkemedel] Financed by the Swedish Competition Authority [Konkurrensverket]. Oct. 2018- Sept. 2020. Project leader: David Granlund.

Within- and across-consumer learning and structural state dependence. Financed by the Jan Wallander and Tom Hedelius Foundation and the Tore Browaldhs Foundation. July 2016-June 2019. Project leader: David Granlund. Co-applicants Andrew Ching, University of Toronto and David Sundström, Umeå University.

I am a member of The Economic Policy Network.

CV

Articles in international scientific journals

A new approach to estimating state dependence in consumers' brand choices applied to 762 pharmaceutical markets, forthcoming in Journal of Industrial Economics, 2020.

Price competition in pharmaceuticals – evidence from 1303 Swedish markets, with M A Bergman, Journal of Health Economics 61, 1-12, 2018.         Results from three extensions 

Physicians prescribing originals causes welfare losses, with D Sundström, Economics Letters 170, 143-146, 2018.

Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals, with M Bergman and N Rudholm, Oxford Bulletin of Economics and Statistics 79(6), 969-996, 2017.

Federal Subsidization of State Expenditure to Reduce Political Budget Cycles, with T Aronsson, International Tax and Public Finance 24(3), 536-545, 2017.
Free view-only version
Post-refereeing-version

Reforming the Swedish pharmaceuticals market: Consequences for costs per defined daily dose, with M Bergman and N Rudholm. International Journal of Health Economics and Management, 16(3), 201-214, 2016.
Free view-only version
Post-refereeing-version

EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals: Has the Price Competition increased? With M Y Köksal-Ayhan. The B.E. Journal of Economic Analysis and Policy 16(2), 1069–1092, 2016.
Published version

Public provision and cross-border health care, with M Wikström, Forum for Health Economics & Policy 19(2), 157-177, 2016 (Open Access).

Gender Norms, Work Hours, and Corrective Taxation, with T Aronsson, Journal of Behavioral and Experimental Economics 56, 33-39, 2015. (Open Access)

The effect of pharmacies' right to negotiate discounts on the market share of parallel imported pharmaceuticals. The B.E. Journal of Economic Analysis and Policy 15, 1197-1235, 2015.
Published version

Parallel Imports and Mandatory Substitution Reform – A Kick or A Muff for Price Competition? The European Journal of Health Economics, 16(9), 969-983, 2015 (with M Koksal-Ayhan)
Free view-only version
Post-refereeing-version

Introducing waiting times for health care in a labor supply model for sickness absence, with D Andrén, Nordic Journal of Health Economics 3, 34-46, 2014 (Open Access)
WP-version

Present-Biased Preferences and Publicly Provided Private Goods. FinanzArchiv/Public Finance Analysis 70(2), 169-199, 2014. (with T Aronsson)
Post-refereeing-version
WP-version

The prescribing physician's influence on consumer choice between medically equivalent pharmaceuticals. Review of Industrial Organization 41, 207-222, 2012. (with N Rudholm) (The final publication is available at springerlink.com.)
Free view-only version
Post-refereeing-version

Electoral accountability in a country with two-tiered government, Public Choice 148, 531-546, 2011. (The final publication is avialable at www.springerlink.com.)
Free view-only version
Post-refereeing-version

Public goods and optimal paternalism under present-biased preferences, Economics Letters 113, 54-57, 2011 (with T Aronsson).
Post-refereeing-version

Price and welfare effects of a pharmaceutical substitution reform, Journal of Health Economics 29, 856-865, 2010.
Post-refereeing-version

Consumer information and pharmaceutical prices: Theory and Evidence, Oxford bulletin of Economics and Statistics 73(2), 230-254, 2011. (with N Rudholm)
Free view-only version
WP-version
Additional results

The effect of health care expenditure on sickness absence, The European Journal of Health Economics 11, 555-568, 2010 (The final publication available at www.springerlink.com.)
Free view-only version
Post-refereeing-version

Inequality in mortality in Vietnam during a period of rapid transition, Social Science & Medicine 70, 232-239, 2010. (with N T Chuc, H D Phuc and L Lindholm, the final publication)
Post-refereeing-version

Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals? Social Science & Medicine 69, 1643-1650, 2009. (The final publication).
Post-refereeing-version
Additional results

Sickness absence and health care in an economic federation, International Tax and Public Finance 14, 503-524, 2007 (The final publication).
Free view-only version
Post-refereeing-version

Fixed budgets as a cost containment measure for pharmaceuticals, The European Journal of Health Economics 7, 37-45, 2006. (with N Rudholm and M Wikström, the final publication available at www.springerlink.com.)
Free view-only version
WP-version

Thesis:
Economic policy in health care – sickness absence and pharmaceutical costs